All News
Towards More Uniform Methotrexate Dosing in Psoriasis
d
MedPage Today
With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.
Read Article
PsA All the Way – Unmet Needs
Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more dedicated to PsA.
Read Article
Study of 221 active RA pts starting a DMARD showed that Sleep disturbance significantly predicted subsequent pain sensitization and conditioned pain modulation. https://t.co/zcUVaMemXN https://t.co/5timIb0aeG
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Your Lupus Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/5caTUJIYtr https://t.co/wCraFM8SwW
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Japanese study using Mendelian randomization (MR) analysis of the association between coffee consumption, gout & uric acid levels - showing coffee consumption can causally reduce gout risk (OR = 0.50), independent of SUA levels https://t.co/aTGkbKDXMg https://t.co/fJqS4nxvDs
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Study of 1899 ankylosing spondylitis pts(10 RCTs) shows TNFi resp can be predicted - 34% had major resp vs 34% w/ no resp @ wk12. A major resp increased w/ higher CRP, Pt Global & BASDAI-Q2 score & decr w/ higher BMI & BASFI https://t.co/Zo0PFiV3ro https://t.co/FsIiAaykpC
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Free Teaching PDF on "What is Rheumatoid Arthritis" from JAMA https://t.co/gf2TBv3AjD
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Study of 119 SLE pts (30 w CKD) shows urinary galectin-3 binding protein as a biomarker, increased w/ active LN, significantly (p<0.001)correlating w/ SLEDAI, SLICC RAS, histologic activity; higher in proliferative vs membranous LN (p=0.04) https://t.co/uUfwJm7JbE https://t.co/mh61wlBN87
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Infection in lupus is suggested by v. high CRP, PMN-lymph ratio (NLR) Plt-lymph ratio(PLR). Study of 104 hospitalized SLE found all v.high w/ infx & Combined cutoffs of CRP >20 mg/L, NLR >3.5, PLR >151 had 87 sensitivity & 81% specificity for infx https://t.co/OOd5Mftnhl https://t.co/GqSI7HLsbY
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us for Tuesday Night Rheumatology on April 5 at 7pm ET.
Register today!
https://t.co/khydENTDzr https://t.co/mtlfIeyRpc
Links:
Dr. John Cush RheumNow ( View Tweet)
PsA All the Way – All April Long
Join us all April long for our focus on PsA. Tweets, articles, blogs, therapeutic updates and more...all this month!
https://t.co/KEDx73TYHL https://t.co/GaTZ00dQ4N
Links:
Dr. John Cush RheumNow ( View Tweet)
Your Hot Topic Questions from RNL 2022
Rheumatologists questions for Dr. Jack Cush
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022
https://t.co/wpPeIwiCxe https://t.co/UY3gDaVeTv
Links:
Dr. John Cush RheumNow ( View Tweet)
Increased Cancer Risk with Autoimmune Disorders (AID)
The incidence and mortality of cancer among AID was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
https://t.co/T2WkOWp0cA https://t.co/iNJioAvrIe
Links:
Dr. John Cush RheumNow ( View Tweet)
Heart Risks Elevated in RA Patients Despite Biologic Tx
Hopes that biologic drugs for RA would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.
https://t.co/qUYG3U2Ind https://t.co/oCpNnDmxIX
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/sjwVaNjK6x
Dr. John Cush RheumNow ( View Tweet)
Systematic lit review of 5694 CTD pts (SLE, RA, IIM, SSc) admitted to the ICU shows overall risk of mortality was 33%. ICU admits mainly for sepsis (43%), flares(40%). Mortality risk was 70% in IIM, 40% SSc, 35% SLE subgroup, 20% RA. https://t.co/ubVujkLCNy https://t.co/nnJdO36imK
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort hospital study of 228 children with MIS-C; 215 patients (median age 8 yrs, 63% boys) shows that orticosteroid monotherapy is a reasonable management option for a subset of patients with MIS-C, particularly those with mild disease https://t.co/HLSR5zOseU https://t.co/5z7I9SVcxI
Links:
Dr. John Cush RheumNow ( View Tweet)
#PsA Biologic initiation was associated with a SMALL drop in NSAIDs (51.1 to 42.5%); glucocorticoids (57.4 to 46.9%) and opioids (38.1 to 33.8%) (Initial vs 12 mos later). Pain Rx use study in 5681 PsA, 2180 AS, & 34,047 RA pts #PsAlways https://t.co/wyrT9CVNq8 https://t.co/8vl7e2a63n
Links:
Dr. John Cush RheumNow ( View Tweet)
Korean study shows #RA is assoc w/ a risk of primary open-angle glaucoma, esp within 2 yrs of Dx & if >75 yrs. Study of 2049 older incident RA pts; POAG risk higher in RA than the matched controls (HR 1.44), 1st 2 yrs (HR 1.83), >75 yrs (HR 2.12) https://t.co/IvPw5InSis https://t.co/dkrK6RvRKE
Links:
Dr. John Cush RheumNow ( View Tweet)
Danish study of opioids in psoriasis (n 4016), PsA (847) & controls (3490). Opioid Use within 12 months seen in 9% general population, 14.2% psoriasis without PsA, & 22.7% concomitant PsA pts. Joint pain incr analgesic use (OR 3.72) #PsAlways https://t.co/WKrA8sChyN https://t.co/9FLq4mKz7V
Links:
Dr. John Cush RheumNow ( View Tweet)